Redeye updates its outlook on Hansa Biopharma, anticipating improved launch support during 2024 and pipeline progress over the next 12 months. A growing number of countries and centres have added to the European launch, and the Eurotransplant program is also resulting in more patients using Idefirix regularly. Our Base Case remains SEK120 with a Bull Case of SEK220 and a Bear Case of SEK15.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/